Company intelligence / Profile preview
GC Cell
Yongin-si, Gyeonggi-do, Koreagccell.com ↗
- Ownership
- Public · 144510
- Development stage
- Commercial
01
Overview
GC Cell has commercialized Immuncell-LC, an autologous CIK & CTL therapy approved in Korea since 2007 for adjuvant treatment of hepatocellular carcinoma. The company is advancing a robust pipeline of allogeneic NK and CAR-NK cell therapies targeting various cancers, with several candidates in preclinical to early clinical stages. Over 10,000 patients have been treated with their solid tumor therapy.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Autologous cell therapies (CIK, CTL)Allogeneic NK cell therapiesCAR-NK cell therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Artiva BiotherapeuticsBioCentriq
04
Financials
- Market cap
- $110.3M
- Total revenue
- $122.3M
- Enterprise value
- $189.3M
Beyond the preview
Go deeper on GC Cell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC Cell.